Despite its promise as a marker for neuronal injury, CSF NfL levels only modestly differed between older adults with AD and normal cognition and serial sampling showed its levels to decrease — vs. increase like Tau or Aβ40 — over time in older adults [32, 33]. The gene discussed is MAPT; the disease is Alzheimer disease.